Premium
Intracavernosal Invicorp as a second line injection therapy for erectile dysfunction after failure of alprostadil
Author(s) -
Bazo A. E.,
McAllister B. J.,
Terry T.
Publication year - 2020
Publication title -
international journal of urological nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.184
H-Index - 8
eISSN - 1749-771X
pISSN - 1749-7701
DOI - 10.1111/ijun.12247
Subject(s) - medicine , priapism , erectile dysfunction , incidence (geometry) , penis , anesthesia , surgery , optics , physics
We retrospectively reviewed 51 men who switched to Invicorp intracavernosal therapy following failure of treatment, or development of pain, with alprostadil intracavernosal injections. Invicorp was successful in 61% of alprostadil non‐responders, with no reported penile pain. Three patients (6%) were admitted with priapism which was appropriately treated. Invicorp proved successful in two thirds of the patients who had failed to respond to intracavernosal alprostadil. Invicorp is an excellent alternative for alprostadil non‐responders, proving successful in 61% of this group. Unlike alprostadil injection, Invicorp users did not experience penile pain after the injection and experienced a 50% reduction in incidence of priapism.